Diagnostics & Informatics

The current state

as of

Diagnostics & Informatics is converging from separate test, software, and record-keeping markets into integrated clinical data platforms spanning instruments, bioinformatics, pathology, imaging, and EHR workflows. In 2026, the strategic center of gravity is shifting toward regulated AI, cloud-connected interoperability, decentralized testing, and precision diagnostics, while reimbursement pressure and installed-base economics reward vendors that control both workflow and recurring data or consumables revenue.

What’s shaping Diagnostics & Informatics right now

  • Reimbursement compression is forcing labs and providers to favor diagnostics that prove clinical utility, faster turnaround, and lower total workflow cost.
  • Interoperability mandates across EHRs, LIS/LIMS, imaging, and instruments are reshaping product architecture because disconnected systems increasingly block procurement and deployment.
  • Care decentralization is moving testing into pharmacies, clinics, and homes, increasing demand for portable platforms and software that supports distributed result management.
  • Precision medicine is expanding demand for molecular, genomic, and multimodal diagnostics that require richer bioinformatics and treatment-linked reporting.
  • Regulatory scrutiny of AI-enabled and blood-based diagnostics is becoming a market gatekeeper because clearance now determines trust, reimbursement pathways, and adoption speed.

Dynamics on the rise and in decline

Rising

  • Platform consolidation

    Large diagnostics, imaging, and healthcare IT vendors are acquiring specialized bioinformatics and workflow software to bundle integrated suites, compressing demand for standalone point solutions.

  • Installed-base competition

    As analyzer and core informatics placements lock in long-term recurring reagent, service, and data-management revenue, competitors intensify efforts to win and retain installed bases.

  • Premium vs Niche Pricing

    Pricing is splitting as buyers increasingly favor premium integrated platforms that deliver compliance and AI value, while lower-cost niche tools compete on specialization or regional fit.

This week’s brief

Earlier briefs

View all →

Tracked trends

View all →
  • CDx Platformization — Regulatory wins in Japan and the U.S. are recasting companion diagnostics as scalable platforms that support therapy selection, pharma partnerships, and recurring revenue.
  • China Neurology Biomarkers — Quanterix and Innovita are turning biomarker platforms into regulated neurology testing infrastructure in China, with approvals that expand both clinical reach and recurring assay revenue.
  • State-by-State Coverage — Commercial payers and CMS are pressuring diagnostic economics, shifting value toward assays that can prove repeat-use utility and navigate tighter coverage rules.
  • Therapy-Specific Liquid Biopsy — Natera’s Japan approval highlights a key shift in liquid biopsy: the strongest commercial opportunities now come from therapy-linked use cases, not broad screening promises.
  • IVDR Audit Bottlenecks — Stricter EU IVDR audits are making certification capacity and compliance execution the new bottlenecks for IVD market access.

Deep dive

What macro forces are shaping diagnostics and informatics in 2026?
In 2026, diagnostics and informatics are being shaped by regulatory pressure, reimbursement and cost containment, AI-driven digital transformation, interoperability demands, supply-chain risk, and the shift toward decentralized care. AI is moving deeper into workflows across imaging, labs, and genomics, while cloud-based platforms and automation are becoming the default operating model. Precision medicine, molecular diagnostics, and connected data ecosystems are expanding as providers seek faster, more actionable results. At the same time, consolidation and competitive realignment are changing how vendors scale and compete.
What major developments have reshaped diagnostics and informatics recently?
Recent shifts in diagnostics and informatics have centered on regulatory validation, AI deployment, and platform consolidation. FDA clearance of a blood-based Alzheimer’s test marked an important step for routine clinical use of blood diagnostics, while digital pathology vendors began embedding AI tools directly into workflow software. At the same time, laboratory informatics continued moving toward cloud-based and AI-enabled platforms, and acquisitions such as Qiagen’s purchase of Genoox showed ongoing consolidation in bioinformatics software. Overall, the industry is moving from standalone innovation toward regulated, interoperable, and workflow-integrated diagnostic systems.
What are the main competitive dynamics in diagnostics and informatics in 2026?
In 2026, diagnostics and informatics is being shaped by ongoing consolidation, with larger healthcare IT, imaging, and diagnostics vendors absorbing smaller point solutions and pushing the market toward integrated platforms. Pricing is splitting between premium, AI-enabled enterprise offerings and lower-cost commoditized tools, while implementation and interoperability requirements continue to limit pricing power in complex deployments. New entrants are still coming in through cloud, AI, and niche bioinformatics products, especially where legacy systems leave workflow gaps. The value chain is also shifting from standalone software or instruments toward recurring revenue from consumables, services, installed base lock-in, and workflow ownership.
How are diagnostics and informatics changing in 2026?
In 2026, diagnostics and informatics are being reshaped by AI and generative AI, digital pathology, decentralized and at-home testing, cloud-connected platforms, and multi-omics molecular diagnostics. These technologies are moving testing and interpretation closer to patients while making workflows more software-driven and data-intensive. The value chain is shifting from standalone lab results toward integrated data capture, analysis, and decision support across hospitals, homes, pharmacies, and remote-monitoring settings. This is also accelerating the use of predictive monitoring, portable molecular systems, and interoperable informatics infrastructure.
Who are the leading players in diagnostics and informatics today?
The diagnostics and informatics market is led by large incumbents such as Siemens Healthineers, GE HealthCare, Philips, Roche, Thermo Fisher Scientific, Danaher, Quest Diagnostics, Abbott, Oracle, Epic, and McKesson. Challengers include scaled companies like Labcorp, Agilent, Bio-Rad, bioMérieux, IQVIA, Optum, Cognizant, Wipro, Health Catalyst, FUJIFILM, and Merative, which compete through software, automation, and workflow integration. Emerging players are increasingly focused on precision diagnostics, AI, and cloud-native informatics, with names such as Natera, Guardant Health, Tempus, Grail, Digital Diagnostics, Abridge, AITRICS, AdviNOW Medical, Schrödinger, Certara, Dotmatics, LabVantage, and Azenta. Overall, the market is shaped by a mix of entrenched installed bases, software-led challengers, and fast-growing data-driven innovators.
What developments signal major shifts in diagnostics and informatics?
Major shifts in diagnostics and informatics are developments that change how testing is performed, analyzed, integrated, or reimbursed, rather than simple product updates. Examples include AI that becomes embedded in lab and imaging workflows, migration of core systems to cloud or hybrid architectures, and interoperability or regulatory requirements that force broader data exchange and auditability. Decentralized testing, such as point-of-care, at-home, and remote diagnostics, also signals a structural change because it moves testing outside the central lab. Advances in precision medicine, automation, and advanced biomarker testing are significant when they alter throughput, staffing, data complexity, or clinical decision-making at scale.

Stay ahead, get your weekly Diagnostics & Informatics brief in your inbox